DarioHealth Launches into the German Diabetes Market
An Estimated 10% of 82 Million German Population Living with Diabetes
DarioHealth Products Now Available Globally in 9 Countries
Oct 3, 2017
CAESAREA, Israel, Oct. 3, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced it expands its global reach with a successful launch into the German market, making its smart diabetes platform available for the first time in the EU's largest market, both by population and GDP.
With this launch, DarioHealth is now commercially available in 9 countries around the world. DarioHealth will operate its direct-to-consumer channel, leveraging its in-depth knowledge from other markets to provide new opportunities for more than 8 million Germans living with diabetes.
Erez Raphael, Chairman and CEO of DarioHealth, commented, "Our technology can help guide consumers to analyze and personalize their diabetes treatment in effort to increase better clinical outcomes. We've received tremendous positive feedback about the Dario smart diabetes solution and we look forward to providing the German market with an unrivaled method for self-diabetes management.
"From a business perspective, this is a very big achievement for us. We've successfully expanded our international market presence, allowing us to capitalize on the most cost-effective markets as we bring personalized healthcare management to diabetes and pre-diabetes patients around the world."
DarioHealth expects the launch into the German market to help the Company reach its Q4 revenue goals and FY2017 annual milestones. Diabetes is on the rise in Germany, with an estimated ten percent of its 82 million population living with this chronic disease.
About DarioHealth Corp.
DarioHealth Corp. is a leading global digital health company serving tens of thousands of users with dynamic mobile health solutions. We believe people deserve the best tools to manage their treatment, and harnessing big data, we have developed a unique way for our users to analyze and personalize their diabetes management. With our smart diabetes solution, users have direct access to track and monitor all facets of diabetes, without having the disease slow them down. The acclaimed Dario™ Blood Glucose Monitoring System all-in-one blood glucose meter and native smartphone app gives users an unrivaled method for self-diabetes management. DarioHealth is headquartered in Caesarea, Israel with a regional office in Burlington, Massachusetts. For more information, visit http://mydario.investorroom.com/.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, when the Company describes the expectations of the launch into the German market, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate and Media Contact
DarioHealth Investor Relations Contact
SOURCE DarioHealth Corp.